• Rahul Sima Kauvery Hospital, Chennai
Keywords: Consent Process, Covid-19, Covid-19 Vaccine, Epidemiology, Healthcare Workers


At present there is no effective therapy for COVID-19 and all current therapies based on previous evidence of drugs and hypotheses and are being used with limited evidence. This applies to the vaccine as well. Researchers face huge challenges in generating high-quality data while putting scientific and ethical principles into practice in the face of restriction of movement and lockdowns. It is clear that inequalities related to social determinants of health are actually magnified during a crisis. ‘Sheltering in place’ does not inflict hardship equally on all people. In this article we look at the challenges to medical research from an epidemiological perspective, including data collection and patient selection, choice of drugs for research, pharmaceutical challenges including those posed by governments and vaccines, and challenges to clinical research: consent, funding and the role of the doctors.

Author Biography

Rahul Sima, Kauvery Hospital, Chennai

Dr Rahul Sima is a Surgeon currently pursuing his Diplomate of National Board in Vascular Surgery at Kauvery Hospital, Chennai. He also teaches post graduate surgical students. He holds other degrees in the field of medicine and hospital administration, and has published extensively in medical journals. He has a background in theology and is avidly interested in the field of bioethics. He is currently a member of the Bangalore Bioethics Forum.


Bhatt, “Clinical Trials during COVID-19 Pandemic,” 59-63.

C. Huang, L. Huang, Y. Wang, X Li, L. Ren, X. Gu,L. Kang, L. Guo, M. Liu, X. Zhou, J. Luo, Z. Huang, S. Tu, Y. Zhao, L. Chen, D. Xu, Y. Li, C. Li, L. Peng, Y. Li, W. Xie, D. Cui, L. Shang, G. Fan, J. Xu, G. Wang, Y. Wang, J. Zhong, C. Wang, J. Wang, D. Zhang, B. Cao,“6-Month Consequences of COVID-19 in Patients Discharged from Hospital: ACohort Study,” Lancet 397, 10270 (16 Jan 2021) 220-232.

C.M. Coopersmith, M. Antonelli, S.R. Bauer, C.S. Deutschman, L.E. Evans, R. Ferrer, J. Hellman, S. Jog, J. Kesecioglu, N. Kissoon, I. Martin-Loeches, M.E. Nunnally, H.C.
Prescott, A. Rhodes, D. Talmor, P. Tissieres, D. De Backer,“The Surviving Sepsis Campaign: Research Priorities for Coronavirus Disease 2019 in Critical Illness,” Crit Care Med. 49, 4 (Apr 01, 2021) 598-622.

Centers for disease control and prevention, “Vaccines and Immunizations,”

E.G. Price-Haywood et al., “Hospitalization and Mortality among Black Patients and White Patients with COVID-19,” N Engl J Med 382 (2020) 2534-43

Eli M. Cahan, Lisa B. Levine, William W. Chin, “The Human Touch—Addressing Health Care’s Workforce Problem amid the Pandemic,” New England Journal of Medicine 383 (2020) e102, doi: 10.1056/NEJMp2020962.


J. Cohen,“The Pandemic Surge at Home is Threatening an Indian Vaccine Maker’s Bid to Protect the World,” Science (2021) (published online May14),

Jerry Avorn, Aaron S. Kesselheim, “Up is down—Pharmaceutical Industry Caution vs Federal Acceleration of Covid-19 Vaccine Approval,” New England Journal of Medicine 383 (2020) 1706-1708, doi: 10.1056/NEJMp2029479.

K. Thomas, “9 Drug Companies Pledge to ‘Stand with Science’ on Corona Virus Vaccines,”New York Times, September 8, 2020,

MoncefSlaoui, Shannon E. Greene, Janet Woodcock, “Bridging the Gap at Warp Speed—Delivering Options for Preventing and Treating COVID-19,” New England Journal of Medicine 383 (2020) 1899-1901, doi: 10.1056/NEJMp2028535.

Monica Webb Hooper, Anna María Nápoles, Eliseo J. Pérez-Stable, “COVID-19 and Racial/Ethnic Disparities,” JAMA 323, 24 (May11, 2020) 2466-2467, doi: 10.1056/NEJMp2028535.

P. Asrani, M.S. Eapen, M.I. Hassan, “Implications of the Second Wave of COVID-19 in India,” DOI:

Pankaj Kumar Panda, Martin R. Stockler, Ashish Gulia, “Clinical Research during Corona virus Disease Pandemic: Challenges and Way forward,” Indian Journal of Medical Sciences 72, 2 (2020) 101-6, doi:10.25259/IJMS_125_2020

R. Zhang, E. Mylonakis,“In inpatients with COVID-19, None of Remdesivir, Hydroxychloroquine, Lopinavir, or Interferon β-1a Differed from Standard Care for In-hospital Mortality,” Ann Intern Med. 174, 2 (Feb 2021)JC17.

S. Balsari, C. Buckee, T. Khanna, “Which COVID 19 Data can you Trust?” Harvard Business Review, May 2020,

Samuel J. Kerstein, “Dignity, Disability, and Lifespan,” Journal of Applied Philosophy 34, 5 (November 2017) 635-50,

WHO briefing of Corona virus,
How to Cite
Sima, R. (2022). COVID-19 AND THE CHALLENGES TO MEDICAL RESEARCH. Asian Horizons, 32-46. Retrieved from